There raising claim that new drugs do not receive a reasonable price in the process of registering domestic new drug list

Pharmaceutical manufacturers industry is claiming that due to the institutional irrationalism, there are increasing cases which get an unkind treatment in the process of registering domestic new drug list. They explained that there is problem on the process of registering domestic new drug list, because alternative drug, development cost, and Price-volume agreement are do not taken into account...